Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of the complement inhibitor Coversin to treat HSCT-associated TMA.

Literature DB >> 29296765

Use of the complement inhibitor Coversin to treat HSCT-associated TMA.

Timothy H J Goodship¹, Fernando Pinto², Wynn H Weston-Davies³, Juliana Silva⁴, Jun-Ichi Nishimura⁵, Miles A Nunn^3,6,7, Ian Mackie⁷, Samuel J Machin⁷, Liina Palm⁴, Jeremy W Pryce⁴, Robert Chiesa⁴, Persis Amrolia⁴, Paul Veys⁴.

Abstract

Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.

Entities: Chemical Disease Species

Year: 2017 PMID： 29296765 PMCID： PMC5728542 DOI： 10.1182/bloodadvances.2016002832

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

21 in total

1. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.

Authors: Sonata Jodele; Kejian Zhang; Fanggeng Zou; Benjamin Laskin; Christopher E Dandoy; Kasiani C Myers; Adam Lane; Jaroslav Meller; Mario Medvedovic; Jenny Chen; Stella M Davies
Journal: Blood Date: 2015-11-24 Impact factor: 22.113

2. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata.

Authors: Miles A Nunn; Ankit Sharma; Guido C Paesen; Sharon Adamson; Olga Lissina; Anthony C Willis; Patricia A Nuttall
Journal: J Immunol Date: 2005-02-15 Impact factor: 5.422

3. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata.

Authors: Natalie J Hepburn; Anwen S Williams; Miles A Nunn; Jayne C Chamberlain-Banoub; John Hamer; B Paul Morgan; Claire L Harris
Journal: J Biol Chem Date: 2007-01-10 Impact factor: 5.157

4. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Authors: Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank
Journal: Blood Date: 2009-10-27 Impact factor: 22.113

5. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors: Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal: Blood Date: 2013-06-27 Impact factor: 22.113

Review 6. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.

Authors: James N George; Xiaoning Li; Jay R McMinn; Deirdra R Terrell; Sara K Vesely; George B Selby
Journal: Transfusion Date: 2004-02 Impact factor: 3.157

7. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors: C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal: N Engl J Med Date: 2013-06-06 Impact factor: 91.245

8. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors: H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal: N Engl J Med Date: 1981-12-03 Impact factor: 91.245

9. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors: Sonata Jodele; Tsuyoshi Fukuda; Alexander Vinks; Kana Mizuno; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ashley Teusink; Fred G Pluthero; Lily Lu; Christoph Licht; Stella M Davies
Journal: Biol Blood Marrow Transplant Date: 2013-12-25 Impact factor: 5.742

10. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.

Authors: Viviana P Ferreira; Andrew P Herbert; Claudio Cortés; Kristi A McKee; Bärbel S Blaum; Stefan T Esswein; Dusan Uhrín; Paul N Barlow; Michael K Pangburn; David Kavanagh
Journal: J Immunol Date: 2009-06-01 Impact factor: 5.422

13 in total

Review 1. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Authors: Samuel A Merrill; Robert A Brodsky
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 2. Clinical promise of next-generation complement therapeutics.

Authors: Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal: Nat Rev Drug Discov Date: 2019-07-19 Impact factor: 84.694

Review 3. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors: J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal: Bone Marrow Transplant Date: 2017-10-02 Impact factor: 5.483

Review 4. Complementopathies and precision medicine.

Authors: Eleni Gavriilaki; Robert A Brodsky
Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808

5. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.

Authors: Sonata Jodele; Christopher E Dandoy; Adam Lane; Benjamin L Laskin; Ashley Teusink-Cross; Kasiani C Myers; Gregory Wallace; Adam Nelson; Jack Bleesing; Ranjit S Chima; Russel Hirsch; Thomas D Ryan; Stefanie Benoit; Kana Mizuno; Mikako Warren; Stella M Davies
Journal: Blood Date: 2020-03-26 Impact factor: 22.113